Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brent Mabey

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Obstetrics and Gynecology|May 21, 2026
Prenatal Cell-Free DNA Screening With Fetal Fraction Amplification at 6-9 Weeks of GestationLorraine Dugoff, Brent Mabey, Jhett Bordwell, et al.
JCO Precision Oncology|January 12, 2023
Cancer Risk Associated With <i>PTEN</i> Pathogenic Variants Identified Using Multigene Hereditary Cancer Panel TestingShelly Cummings, Andrew Alfonso, Elisha Hughes, et al.
Cancer Genetics|October 15, 2023
Breast and colorectal cancer risks among over 6,000 CHEK2 pathogenic variant carriers: A comparison of missense versus truncating variantsErin Mundt, Brent Mabey, Irene Rainville, et al.
Prenatal Diagnosis|April 16, 2024
High positive predictive value 22q11.2 microdeletion screening by prenatal cell-free DNA testing that incorporates fetal fraction amplificationCarly Hammer, Summer Pierson, Ashley Acevedo, et al.
Journal of the National Cancer Institute|April 21, 2022
Pancreatic Ductal Carcinoma Risk Associated With Hereditary Cancer-Risk GenesAnna Gardiner, John Kidd, Maria C Elias, et al.
Plos One|May 6, 2024
External validation of a multi-biomarker-based score for predicting risk of cardiovascular disease in patients with rheumatoid arthritisEric H Sasso, Brent Mabey, Darl D Flake, et al.
Urologic Oncology|December 1, 2020
Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancerDavid S Morris, J Scott Woods, Byard Edwards, et al.
Frontiers in Pharmacology|November 17, 2025
Persistent benefit of pharmacogenomic testing on initial remission and response rates in patients with major depressive disorderDaniel Hain, Andria L Del Tredici, Ryan B Griggs, et al.
Arthritis Research & Therapy|December 5, 2020
Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patientsJeffrey R Curtis, Fenglong Xie, Cynthia S Crowson, et al.
Personalized Medicine|September 11, 2020
Clinical validity of a gene expression signature in diagnostically uncertain neoplasmsLoren E Clarke, Brent Mabey, Darl D Flake Ii, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Obstetrics and Gynecology|May 21, 2026
Prenatal Cell-Free DNA Screening With Fetal Fraction Amplification at 6-9 Weeks of GestationLorraine Dugoff, Brent Mabey, Jhett Bordwell, et al.
JCO Precision Oncology|January 12, 2023
Cancer Risk Associated With <i>PTEN</i> Pathogenic Variants Identified Using Multigene Hereditary Cancer Panel TestingShelly Cummings, Andrew Alfonso, Elisha Hughes, et al.
Cancer Genetics|October 15, 2023
Breast and colorectal cancer risks among over 6,000 CHEK2 pathogenic variant carriers: A comparison of missense versus truncating variantsErin Mundt, Brent Mabey, Irene Rainville, et al.
Prenatal Diagnosis|April 16, 2024
High positive predictive value 22q11.2 microdeletion screening by prenatal cell-free DNA testing that incorporates fetal fraction amplificationCarly Hammer, Summer Pierson, Ashley Acevedo, et al.
Journal of the National Cancer Institute|April 21, 2022
Pancreatic Ductal Carcinoma Risk Associated With Hereditary Cancer-Risk GenesAnna Gardiner, John Kidd, Maria C Elias, et al.
Plos One|May 6, 2024
External validation of a multi-biomarker-based score for predicting risk of cardiovascular disease in patients with rheumatoid arthritisEric H Sasso, Brent Mabey, Darl D Flake, et al.
Urologic Oncology|December 1, 2020
Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancerDavid S Morris, J Scott Woods, Byard Edwards, et al.
Frontiers in Pharmacology|November 17, 2025
Persistent benefit of pharmacogenomic testing on initial remission and response rates in patients with major depressive disorderDaniel Hain, Andria L Del Tredici, Ryan B Griggs, et al.
Arthritis Research & Therapy|December 5, 2020
Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patientsJeffrey R Curtis, Fenglong Xie, Cynthia S Crowson, et al.
Personalized Medicine|September 11, 2020
Clinical validity of a gene expression signature in diagnostically uncertain neoplasmsLoren E Clarke, Brent Mabey, Darl D Flake Ii, et al.
Pageof 2